Prestige Consumer Healthcare Inc. $PBH Shares Bought by First Trust Advisors LP

Key Points

• First Trust Advisors LP increased its Prestige Consumer Healthcare stake by 137.5% in the first quarter, owning 37,395 shares valued at approximately $2.2 million. Institutional investors and hedge funds collectively own 99.95% of PBH.
• Prestige exceeded quarterly expectations, reporting adjusted EPS of $0.98 and revenue of $265.7 million, up 6.5% year over year. Management also raised fiscal 2027 guidance and reported stronger free cash flow, though GAAP earnings, margins and net income declined amid acquisition and interest costs.
• Analyst sentiment remains mixed: PBH has an average “Hold” rating and a consensus price target of $70.75, while the company carries approximately $2 billion in net debt as it integrates recent acquisitions.

First Trust Advisors LP lifted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 137.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 37,395 shares of the company's stock after buying an additional 21,649 shares during the quarter. First Trust Advisors LP owned approximately 0.08% of Prestige Consumer Healthcare worth $2,216,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. UMB Bank n.a. boosted its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company's stock valued at $26,000 after acquiring an additional 219 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $29,000. Torren Management LLC acquired a new stake in Prestige Consumer Healthcare in the fourth quarter worth about $35,000. Caitong International Asset Management Co. Ltd lifted its holdings in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock worth $35,000 after purchasing an additional 236 shares during the period. Finally, Danske Bank A S bought a new position in Prestige Consumer Healthcare in the 3rd quarter valued at about $37,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on PBH. Zacks Research downgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Monday, May 18th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a research note on Friday, May 15th. Finally, Oppenheimer cut Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Hold" and a consensus target price of $70.75.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment.
• Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results
• Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031.
• Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target
• Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability.
• Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $54.92 on Friday. The company has a quick ratio of 2.25, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. The business's 50-day moving average price is $48.82 and its 200 day moving average price is $56.06. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $71.07. The firm has a market cap of $2.60 billion, a P/E ratio of 15.38, a PEG ratio of 1.69 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company had revenue of $265.71 million during the quarter, compared to the consensus estimate of $250.34 million. During the same period in the prior year, the company earned $0.90 EPS. Prestige Consumer Healthcare's revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.6 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source